A MASTER PROTOCOL TO EVALUATE THE LONG-TERM SAFETY OF PIRTOBRUTINIB
- Registry ID
- J2N-MC-JZNY
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Last update
- 2025-12-08
Conditions
- LYMPHOCYTIC LEUKEMIA
- LYMPHOMA
Related clinical trials
- A PHASE III, MULTICENTRE, OPEN-LABEL, RANDOMISED STUDY EVALUATING THE EFFICACY
AND SAFETY OF R-MINI-CHOP × 2 FOLLOWED BY AZD0486 VERSUS R-MINI-CHOP × 6
IN ELDERLY OR UNFIT PARTICIPANTS WITH NEWLY DIAGNOSED LARGE B-CELL LYMPHOMA
(SOUNDTRACK-D2)
- A PHASE 1 / 2, OPEN-LABEL STUDY OF REC-1245 IN PARTICIPANTS WITH UNRESECTABLE,
LOCALLY ADVANCED, OR METASTATIC CANCER
- LORATADINE FOR THE PREVENTION OF BONE PAIN CAUSED BY GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) DURING STEM CELL MOBILIZATION
- A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314)
- SINGLE-ARM, PHASE 2 STUDY OF VALEMETOSTAT TOSYLATE MONOTHERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA GRADE 1 TO 3A OR R/R MARGINAL ZONE LYMPHOMA (INMIND)
View on source registry